Circio Holding ASA Total Liabilities
Circio Holding ASA total liabilities. Based on the latest financial reports, Circio Holding ASA (CRNA) has total liabilities worth Nkr26.70 Million NOK (≈ $2.81 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Circio Holding ASA's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Circio Holding ASA (2020–2025)
Total liabilities of Circio Holding ASA from 2020 to 2025. This chart illustrates how Circio Holding ASA's total liabilities have evolved over time, based on quarterly financial data.
Circio Holding ASA Competitors by Total Liabilities
The table below lists competitors of Circio Holding ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FLAT GLASS GROUP H YC-25
F:72T
|
Germany | €19.77 Billion |
|
Fujian Superpipe
SHE:300198
|
China | CN¥1.60 Billion |
|
Médica Sur S.A.B. de C.V
MX:MEDICAB
|
Mexico | MX$2.19 Billion |
|
Braskem S.A.
SA:BRKM3
|
Brazil | R$90.56 Billion |
|
FutureCrest Acquisition Corp.
NYSE:FCRS
|
USA | $13.25 Million |
|
AGORA INC. SP.ADS/4 CL.A
F:9AG1
|
Germany | €169.61 Million |
|
TRANSILVANIA INVESTMENTS ALLIANCE S.A.
RO:TRANSI
|
Romania | RON204.33 Million |
|
Diamond Food Indonesia PT
JK:DMND
|
Indonesia | Rp1.64 Trillion |
Liability Composition Analysis (2020–2025)
This chart breaks down Circio Holding ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CRNA asset base.
Liquidity & Leverage Metrics
Circio Holding ASA Total Liabilities Ratios Explained
Circio Holding ASA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 20.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Circio Holding ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Circio Holding ASA (2020–2025)
The table below shows the annual total liabilities of Circio Holding ASA from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Nkr23.25 Million ≈ $2.45 Million |
-32.30% |
| 2024-12-31 | Nkr34.34 Million ≈ $3.61 Million |
-72.36% |
| 2023-12-31 | Nkr124.25 Million ≈ $13.07 Million |
+26.99% |
| 2022-12-31 | Nkr97.85 Million ≈ $10.30 Million |
-33.68% |
| 2021-12-31 | Nkr147.54 Million ≈ $15.53 Million |
-0.41% |
| 2020-12-31 | Nkr148.15 Million ≈ $15.59 Million |
-- |
About Circio Holding ASA
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in hu… Read more